Tasly Launches Phase III Study of Compound Danshen Dripping Pills in the Treatment of Acute Altitude Sickness in the United States

Article source: Medical Rubik's Cube Info

Recently, Tasly registered a Phase III clinical study on the prevention and treatment of acute altitude sickness (AMS) with T89 (Compound Danshen Dripping Pills) on the American Clinical Network

According to Tasly’s announcement, the prevention and treatment of acute altitude sickness (AMS) is a new indication discovered in many real-world clinical observations of T89

The compound Danshen dripping pill is a modern and innovative Chinese compound medicine developed exclusively by Tasly, which is mainly used for the prevention and treatment of cardiovascular diseases.

After that, Tasly submitted the new drug application (NDA) related approval information for T89 treatment of CSA to the FDA, and held a meeting with the FDA

Acute altitude sickness (AMS) is a common hypoxic disease that is unique to altitude.

T89 is the world's first Chinese compound medicine to apply for new drug listing in the United States